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Sensing/Pacing Lead Complications With
Implantable Cardioverter-Defibrillator : Worl
From the Guardian ATP 4210 Clinical Trial
Objectives. This report describes the sensing/pacing lead com-
plications
that developed during a worldwide clinical trial of a new
implantable cardioverter-defibrillator .
Background. The reliability of the leads used for sensing and
pacing with the implantable cardioverter-defibrillator has not
been adequately studied .
Methods. The Guardian ATP 4210 was implanted in 302
patients . The sensing/pacing leads consisted of either two unipolar
epicardial electrodes or a bipolar endocardial electrode from a
variety of manufacturers .
Results . During a mean follow-up period of 389 days, 39
patients (12 .9%) required reoperation because their device devel-
oped sensingipacing lead system complications . The most common
clinical presentation was device oversensing (multiple tachycardia
or noise detections or inappropriate shocks), which was observed
in 27 patients, whereas elevated pacing thresholds were seen in 10
patients. Forty-one (11 .8%) of 347 implanted lead systems re-
quired revision. The mean time to revision was 156 ± 145 days .
The sensing lead of the implantable cardioverter-defibrillator
is required for detection of ventricular tachyarrhythmias
and for synchronization of the implantable cardioverter-
defibrillator discharge . In newer devices, this lead system
may also be used for demand ventricular pacing and for
antitachycardia pacing to terminate ventricular arrhythmias .
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Actuarial lead survival rate at 1 and 3 years was 89% and 79%,
respectively . Epicardial lead systems required significantly (p <
0.05) more revision than did endocardial systems, but when
adapter problems were excluded, the revision rates of epicardial
and endocardial leads were similar . Causes of lead system failures
included adapter connection problems, lead dislodgement and
insulation disruption . Predictors of lead revision were use of an
epicardial lead system or an adapter .
Conclusions. A high rate of sensing/pacing lead complications
was found with this newer generation implantable cardioverter-
defibrillator . The enhanced diagnostic and data storage capabili-
ties of this implantable cardioverter-defibrillator facilitated the
recognition and troubleshooting of these complications . These
findings emphasize the need for careful surveillance and testing of
implantable cardioverter-defibrillator sensing/pacing leads during
follow-up .
(J Am Coll Cardiol 1994 ;23:123-32)
The sensing/pacing lead system usually consists of either a
bipolar transvenous right ventricular electrode or two uni-
polar epicardial electrodes .
Although the long-term reliability and performance of
leads used with permanent pacemakers have been previ-
ously examined in detail (1-3), less attention has been
given to the sensing/pacing leads used with implantable
cardioverter-defibrillators
. In this report, we describe the
worldwide clinical experience, collected in a prospective
fashion, with the sensing/pacing lead systems used with a
newer generation implantable cardioverter-defibrillator
(Guardian ATP 4210, Telectronics Pacing Systems, Inc .) .
The performance of epicardial and endocardial sensing/
pacing lead systems were compared, and the problems
related to adapters and extenders were
reviewed. In
addition, the utility of the enhanced diagnostic and data
storage capabilities of this device was assessed with regard
to the ability to diagnose lead- or adapter-related complica-
tions .
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Table 1. Clinical Characteristics of Patients With an
Implantable Cardioverter-Defibrillator and Sensing/Pacing
Lead System Complications
All Study Pts Pts With a Lead
With an [CD Complication
(n = 302)
	
(n = 39)
Values presented are mean value ± SD or number or percent
. CAD =
coronary artery disease
; [CD = impla ratable card ioverter-defibrillator
; LV
=
left ventricular
; NYHA = New York Heart Association
; Pts = patients ;
VF = ventricular fibrillation
; VT = ventricular tachycardia .
Methods
Study patients. During the period between December 4,
198 and December 31, 1991, 302 patients were enrolled in
this study at 51 participating centers worldwide (see Appen-
dix). Approval of the study protocol was obtained from each
institutional review board, and written, informed consent was
obtained from each patient . All patients underwent implanta-
tion of the Guardian ATP 4210 multiprogrammable pacemaker
cardioverter-defibrillator. Three patients underwent two im-
plantations because of an implantable cardioverter-defibrillator
failure unrelated to the sensing/pacing lead system . These
failures included a cracked solder joint, damage from exter-
nal defibrillation and a random implantable cardioverter-
defibrillator component failure
. One patient's implantable
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cardioverter-defibrillator was explanted because of an infec-
tion, and after resolution a new device was implanted . The
clinical characteristics of the study patients are shown in
Table 1 .
Description of the implantable cardioverter-defibrillator.
The Guardian ATP 4210 provides automatic detection and
treatment of bradycardia, ventricular tachycardia and ven-
tricular fibrillation . The detection criterion is satisfied when
at least X of the Y most recent sensed intervals are shorter
than or equal to the detection interval . The tachycardia
detection criterion may be set at 8 of 10, 12 of 15 or 16 of 20
intervals. Noise detection is fixed at 7 of 10 intervals
<100 Ins, whereas the fibrillation detector is set at 8 of 10
intervals X250 ms (240 beats/min). The onset detection
algorithm, which can be inactivated, looks for a sudden,
sustained decrease in detection intervals. After tachyar-
rhythmia detection, the Guardian ATP 4210, again using an
X of Y algorithm, reconfirms the presence of tachyarrhyth-
mia and then classifies the tachyarrhythmia as slow or fast
ventricular tachycardia or ventricular fibrillation before de-
livery of each antitachycardia pacing train or cardioversion-
defibrillation shock . Sensing during sinus rhythm, ventricu-
lar tachycardia and ventricular fibrillation is programmable
using a fixed gain between 1 .0 and 5 .7 mV. After tachycardia
detection and entry into the shock therapy state, sensitivity
automatically increases by a programmable percent of the
initial sensitivity. Programmable therapies include synchro-
nized low and high energy cardioversion-defibrillation
shocks and antitachycardia and bradycardia (VVI) pacing .
Extensive data storage capabilities are available, includ-
ing event counters and a detailed record of therapy delivered
during episodes of tachyarrhythmia (Fig . l) . Event counters
that summarize clinical events detected by the device in-
clude the number of detections by each of the algorithms
(lachycardia, fibrillation, onset, noise) ; the number of spon-
taneous reversions before confirmation ; the number of suc-
cessful reversions by antitachycardia pacing or shock ther-
apy; the number of times that antitachycardia pacing therapy
accelerated the tachyarrhythmia, and the total number of
shocks delivered to the patient . Data logs from individual
episodes record the date and time of the episode, the
tachycardia cycle length, the algorithm that detected the
tachyarrhythmia, a sensing history of up to 32 intervals
before detection, the therapy that was delivered and the
response to therapy . One-second snapshots of the intracar-
diac electrogram and corresponding main timing events are
available at detection, confirmation and reversion of epi-
sodes.
Surgical implantation . Surgical implantation of the im-
plantable cardioverter-defibrillator and lead systems was
accomplished by standard methods . Epicardial patches were
used in all implants as the cardioversion-defibrillation leads .
The choice of the sensing/pacing lead system was left to the
discretion of the implanting physicians and consisted of
either two unipolar epicardial electrodes screwed into the
ventricular surface or a bipolar endocardial electrode posi-
Age (yr)
61 ± 13 59 = 12
Male/female (%)
84/16 90110
Structural cardiac disease (%)
CAD
71 69
Cardiomyopathy
I 1 8
Other
1 0
None
4 5
Not reported
13 18
LV ejection fraction (""o)
34 ± 13 34 ± 14
NYHA functional class (%)
1
30
20
11
43 41
III 21 8
IV 1 3
None 5 8
Not reported
I I I I
Indication for [CD implantation (%)
VT 63 61
VF 12 13
VT/VF
12 13
Cardiac arrest 8 13
Not reported 5 0
Concomitant drugs (%)
Amiodarone
22 30
Beta-adrenergic blocking agents 10 16
Other antiarrhythmic agents 33 33
Surgical approach (%)
Thoracotomy 30 35
Median sternotomy 26
24
Subcostal 12 14
Subxiphoid 8
5
Abdominal 7 3
Other 16
9
Other implanted devices 4
0
Duration of follow-up (days)
380 ± 210 408 ± 192
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tioned in the right ventricular apex (Tables 2 and 3 list the
manufacturers and models) . In one implant, the sensing/
pacing lead system consisted of an endocardial electrode
(CPI model BT10) combined with a unipolar epicardial
electrode (CPI model 4312) . In all implants with epicardial
sensing/pacing leads, the two unipolar electrodes were con-
nected to the implantable cardioverter-defibrillator by bifur-
cated bipolar adapters (Table 4). During implantation of
Table 2. Epicardial Lead Complications
Total No . Total No. of Lead Insulation Increased
Lead Model
	
Implanted Complications Fracture Failure Threshold
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Figure 1 . Stored data log, and intracardiac electrogram (ICED) from a
single oversensing event due to a sensing/pacing lead problem that was
retrieved from the Telectronics Guardian ATP 4210 . The data log
reveals elapsed time since detection ; tachycardiaa cycle length (TCL) ;
detection sense history, including a graphic display and listing of the 32
RR intervals preceding detection of tachyarrhythmia ; and a 1-s snap-
shot of the intracardiac electrogram . In this example, there is sudden
detection of intervals <100 ms, and the intracardiac electrogram
snapshot reveals noise signals with device detections unrelated to the
intrinsic ventricular electrogram . The noise detection algorithm was
inactivated in this patient . bpm = beats per minute .
endocardial lead systems, adapter extenders were used to
lengthen the endocardial lead to reach the implantable
cardioverter-defibrillator in the abdominal pocket in 90 im-
plants ; bifurcated bipolar adapters were used in 26 implants ;
aiad no adapter or extender was required in 60 implants . The
type of sensingipaciag lead system used was not reported in
3 implants ; the adapter model used was not reported in I I
implants; and whether an adapter was required was not
specified in 7 implants (none of which developed a compli-
cation) .
After lead system implantation, defibrillation threshold
and sensing/pacing testing were performed. The sensing/
pacing lead was required to have a pacing threshold <2 .5 V
at a pulse width of 0 .5 ms, an R wave amplitude >5 mV in
sinus rhythm and a pacing lead impedance between 350 and
1500 R. Sensing was evaluated during sinus rhythm, ventric-
ular fibrillation and, in most cases, during ventricular
tachycardia . Thirty-one patients had an implant pacing
threshold >1 .5 V (mean 2 .3 ± 0.60 V)
. In 11 of these
patients, the pacing lead was a chronic electrode .
Electrophysiologic testing and follow-up
. Patients under-
went electrophysiologic evaluation of device and lead sys-
tem function before hospital discharge and at 2 to 4 months
alter implantation
. This evaluation included ventricular
tachycardia and ventricular fibrillation detection and rever-
sion by the device and measurement of pacing and sensing
thresholds . Patients were seen every 2 months for routine
follow-up or sooner if problems occurred, at which time the
Telectronics
030-222 3 1 0
0 1
030-223 36
4 0 3 1
033-223 2
1 1 0 0
033-571 1 0 0 0 0
033-572 26 1 0 1 0
030-574 1 0 0 0 0
030-575
19 2 1 1 0
325452
8 0 0 0 0
CH
K54
9 1 1 0 0
4312 11 0 0 0 0
4320 1 0 0
0 0
0030 2 0 0
0 0
Possis
1112 2 0 0 0
1113 1 0 0 0 0
1114 22 0
I 1
Daig
501170 1 0
0 0
0
ML150
2 0 o 0 0
ML151 1 0 0 0
0
Intennedics, 47107 I 0 0 0
0
Medtronic
4951 1 0
0 0 0
6917 7
0 0 0 0
SP2139 I 0 0 0 0
Not reported
4 0
o
0
0
Total 162 12 3 6
3
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Table 3. Endocardial Lead Complications
"Exploration and testing without lead revision . tLoose connection to implantable cardioverter-defibrillator . generator replaced without lead revision . +,Model
number not reported .
implantable cardioverter-defibrillator was interrogated, and detections. delivered shocks, spontaneous reversions and
the contents of the data logs and programmed variables were reversions by antitachycardia pacing or shock therapy were
reviewed. Patients were questioned with regard to symptom- obtained . Data logs from individual episodes and snapshots
atic events and shock delivery . The total number of device of intracardiac electrogratns and corresponding main timing
Table 4. Adapter/Extender Complications
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Lead Model
Total No .
Implanted
Total No. of
Complications
Lead
Fracture
insulation
Failure
Increased
Threshold Dislodgement
Poor
Sensing Other
Telectronics
330-201 73 8
2 0 0 4 0 2`
329-201 6
0 0 0 0 0 0 0
033-044 2 0 0
0 0 0 0 0
330-258 3
1 0 0 1 0 0 0
030-224 1 0 0 0
0 0 0 0
033-454 3 0 0
0 0 0 0 0
040-113 3 0 0
0 0 0 0 0
329-259 1
0 0 0 0 0 0 0
CPI. BT10 23 2 0 0 0 '
0 0
Oscor
PY I OOBV 21 2
0 1 1 0 a 0
PY9SBV 8 0 0 0 0
0 0 0
RXIOOTB 1 0 0 0
0 0 0 0
Stockert
010-040 1 1 0 0 0 lit 0 1
BN010!1 4 0 0 0 0 0 0 0
Intermedicst 1 1 0 0 0 0 I
0
Medtronic
5024 7 0 0 0 a 0 0 0
SP2114 1 0 0 0 0 0 0 0
SPI250 3 0 0 0 0 0 0 0
10295A 1 0 0 0 0 0 0 0
4058 1 0 0 0 0 0 0 0
5026 2 0 0 0 0 0 0 0
4024 1 0 0 0 0 0 0 0
10340 2 0 0 0 0 0 0 0
Siemens . IDIOT 7 0 0 0 0 0 0 0
Not reported 5 0 0 0 0 0 0 0
Total 181 15 2 1 2 6 1 3
Model
Total No .
Implanted
Total No_ of
Complications
Adapter
Fracture
Insulation
Failure
Improper
Connection
Adapters
Telectronics
030-308 144 6
2
1 3
033-415 25 5 0 1 4
331-260 6 2 1 0 1
033-260 1 0 0 0 0
330-260 2 0 0 0 0
Medtronic. 5866 2 0 0 0 0
Extenders
Telectronics
033-302 71 3 0 0 3
335.121 12 0 0 0 0
Medtronic, 6984 7 0 0 0 0
Not reported I1 0 0 0 0
Total 281 16 3 2 11
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Figure 2. Main timing events (MTE) (upper
trace) and intracardiac electrogram (ICEG) (low-
er trace) demonstrating oversensing during
transcutaneous manipulation of
the implantable
cardioverter-defibrillator pulse generator in the
abdominal pocket beginning at the arrow . In this
example, intermittent noise was generated be-
cause of an insulation failure of a bifurcated
adapter.
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events were analyzed. Measurements of pacing threshold,
lead impedance and sensing threshold in sinus rhythm were
performed .
Statistical analysis. Life-table survival estimates are re-
ported as mean value ± SE . All other values are reported as
mean value ± SID. A pair of unipolar epicardial leads was
treated as one lead, and failure of one unipolar lead was
considered a failure of the entire lead system . A lead system
was considered to have failed if the lead required revision,
replacement, repositioning or repair, or an adapter was
replaced or reconnected . Lead systems that required oper-
ative exploration with testing, generator replacement or
device reprogramming but without lead revision were con-
sidered to have survived . Chi-square analysis was used to
determine significant differences between categoric vari-
ables . The lead survival curves were generated using the
actuarial life-table method. Epicardial and endocardial sur-
vival curves were compared using the log-rank test . Univari-
ate predictors of lead revisions were determined by using the
chi-square test, whereas a multivariate analysis was per-
formed by using a logistic regression model . Statistical
significance was accepted at p < 0 .05 .
Results
Patients with lead complications . Thirty-nine (12 .9%) of
the 302 patients who underwent implantable cardioverter-
defibrillator implantation developed complications of the
sensing/pacing lead system during a mean follow-up period
of 380 ± 210 days . Lead system revision was performed in 36
patients, and operative exploration with testing but without
revision was performed in three patients . In five patients .
sensing/pacing lead system failures occurred twice and re-
quired a second revision . The clinical characteristics of the
patients whose device developed lead failures were similar
to those of the entire study group (Table 1) . The mean
duration of follow-up in the group requiring lead revision
was 408 ± 192 days (range 0 to 791) .
Clinical presentation . The decision to perform a lead
revision was made by the individual implanting investigators
on the basis of clinical suspicion, the retrieved data logs and
intracardiac electrograms. Oversensing was the most com-
mon clinical presentation . The data logs revealed frequent
tachycardia or fibrillation detection suggestive of a lead
problem in 27 of the 39 patients . These episodes often
occurred at excessively high, nonphysiologic rates ; had large
STAMBL.ER ET AL
. 127
ICD SENSINGiPACtNG LEAD COMPLICATIONS
variations in cycle lengths, and usually reverted spontane-
ously before any therapy was given . Twenty of the '9
patients received single or Multiple shocks that were not
preceded by symptoms suggestive of tachvarrhythmia, sug-
gesting to the investigator that the shock was inappropriate .
Twenty-six (67%) of the patients with lead complications
also had single or multiple detections of noise (7 of 10
detection intervals <100 ms) . In the total group of 302
patients with an implantable cardioverter-defibrillator, 27
additional patients had detections that were stored in the
data logs as noise events . The source of the noise detections
in these patients was unknown ; however, none of these 27
patients underwent lead revision during the study period . It
is doubtful that external sources, such as electrocaul :ery or
alternating current, caused the noise in these patients be-
cause the detections occurred between follow-up visits .
In 20 patients, oversensing was confirmed by using the
intracardiac electrogram recorded from the sensing/pacing
lead along with the marker channel showing implantable
cardioverter-defibrillator-sensed events (Fig . I). In some
patients a lead integrity problem was suspected, but sensing
problems were intermittent and difficult to diagnose . Trans-
cutaneous manipulation of the implantahle cardioverter-
defibrillator in the abdominal pocket while observing the
main timing events and intracardiac electrograms for inap-
propriate sensing or noise was used to confirm the diagnosis
in these cases (Fig . 2) .
Ten patients who required a lead revision had elevated
pacing thresholds, with loss of capture at maximal device
output (7 .5-V amplitude, 1 .0-ms pulse width) in 9 of the 10 .
None of these 10 patients had an initial implant pacing thresh-
old >1.5 V. In one patient the device was stimulating the
abdominal wall muscles around the implantable cardioverter-
defibrillator pocket in association with decreased sensing/
pacing lead impedance . In three patients, the device failed to
sense the QRS complex during sinus rhythm during teleme-
try monitoring and in one patient undersensing of induced
ventricular fibrillation was noted during electrophysiologic
study. No device failed to sense a clinical ventricular tachy-
cardia because of a lead problem, and no patients died
because of a sensing/pacing lead problem .
Sensing/pacing lead system complications. Three hundred
forty-seven sensing/pacing lead system implantations (306
primary implantations, 41 revisions) were performed in the
302 patients in the study . In the 39 patients with sensing!
pacing lead complications, 41 sensing/pacing leads were
128
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SENSEPACE LEAD SYSTEM SURVIVAL BY LEAD TYPE
0
	
i 8 12 I '0 2O 24 25
MONTHS AFTER IMPLANT
F18ure 3 . Comparison of actuarial survival of endocardial and
epicardial sensing/pacing lead systems . The 12-month survival rate
was 91 .6
±
2.4% and 86.3 ± 3.0% for endocardial and epicardial lead
systems, respectively. There was no significant difference (p > 0 .05)
between the two curves by the log-rank test . The numbers above and
below the curves are the number of leads surviving at the various
follow-up intervals for the endocardial and epicardial lead systems,
respectively.
revised, and three operative explorations were performed
without lead revision . The overall incidence of sensing/
pacing lead revision was 11.8%. The mean number of days
from initial implantation to lead revision was 156 ± 145 days
(range 3 to 562). More than 70% of lead revisions occurred
within the 1st 6 months after implantation . The probabilities
of lead survival as assessed by the actuarial life-table method
at 12, 24 and 36 months were 89.0 ± 1.9%, 82.8 ± 2.9% and
79.0 ± 4.7%, respectively (95% confidence intervals 85.3%
to 92.8%, 77.1% to 88.5%, 69.8% to .1%, respectively).
Epicardial lead systems required significantly more revi-
sions than did endocardial lead systems (p < 0 .05) . Sensing!
pacing lead revisions wt.>,•e performed in 25 of the 162
epicardial sensing/pacing lead systems (15 .4%) and in 15 of
the 181 endocardial lead systems (8 .3%) . One lead revision
was performed in a patient with a combined endocardial-
epicardial sensing/pacing lead system. Although epicardial
lead systems tended to have a lower probability of survival
than did endocardial lead systems, there was no significant
difference between the actuarial survival curves for endocar-
dial and epicardial lead systems (Fig . 3).
Three patients with endocardial lead systems developed
complications that required operative exploration with test-
ing, but at the time of operation a lead system revision was
not performed . In one of these patients, the implantable
cardioverter-defibrillator developed oversensing and device
detections during manipulation of the device in the
abdomen
. A loose connection between the header of the
implantable cardioverter-defibrillator pulse generator and an
---4-- EMDOCARDIAL
EPICARDIAL
,7
TO
32 36
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endocardial lead (Stockert model 010-040) was found. Re-
placement of the implantable cardioverter-defibrillator gen-
erator using the existing lead system resolved the problem .
In the other two patients, a sensing/pacing lead system
problem was clinically suspected . However, the cause of the
problem could not be identified in the operating room . The
first of these patients developed a pacing lead impedance
>2,000 11. In the operating room, testing of the sensing/
pacing lead showed appropriate sensing and pacing, and the
cause of the high impedance could not be determined . In
follow-up, the lead impedance remained elevated with
otherwise appropriate lead system function . The second
patient experienced inappropriate shocks and multiple
tachycardia and noise detections that could not be elimi-
nated with device reprogramming In the operating room, a
lead problem could not be identified, and noise detections
could not be recreated . The lead system was not revised, and
during subsequent follow-up the oversensing problem re-
solved.
Three patients developed complications of the sensing!
pacing lead that were managed by device reprogramming
without lead revision. In two of these patients this compli-
cation was related to an increase in pacing threshold, and in
one patient intermittent undersensing was noted that re-
solved with reprogramming of the sensitivity from 2.0 to
1.4 mV .
Causes of complications . Lead system complications
were classified as lead-related (61%) or adapter-related
(39%) (Fig. 4A). Among epicardial lead system complica-
tions, the failure was of one or both of the unipolar epicardial
electrodes in 12 instances and of an adapter in 13 . Among
endocardial lead system revisions, the failure was of the
transvenous lead in 12 instances and of an adapter or
extender in 3 . Thus, when adapter problems were excluded,
the total number (12) of epicardial and endocardial lead
complications was the same .
Among the 25 lead-related complications, the cause was a
lead fracture in 5 (3 epicardial, 2 endocardial), an insulation
break in 7 (6 epicardial, I endocardial), dislodgement of an
endocardial lead in 6, high pacing thresholds in 5 (3 epicar-
dial, 2 endocardial) and poor sensing in 2 (1 endocardial and
l combined endocardial-epicardial) (Fig . 4B). These lead
complications were managed by replacement with a new
lead in 20 cases, by repositioning of the existing lead in 3
cases and by repair of the failed lead in 2 cases of insulation
disruption. In 8 of the 12 epicardial lead failures, the existing
epicardial lead system was replaced with a new endocardial
lead system, whereas none of the endocardial leads were
replaced with epicardial leads .
Sixteen of the 41 lead system revisions were due to
failures of the adapters or extenders . Among the 281 adapt-
ers implanted in the study patients, the overall complication
rate was 5 .7% (Table 4). Thirteen of these adapters were part
of an epicardial lead system, and three were part of an
endocardial lead system . Only 2 of the 60 patients without an
adapter as part of the sensing/pacing lead system required a
.$ACC Vol. 23, No . I
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F' 4. Bar graphs comparing the number of
complications in endocardial and epicardial lead
systems. Complications are classified (A) as lead or
adapter related and are grouped ( ) according to
cause .
A
lead revision . Three adapters developed fractures ; 2 adapt-
ers developed separation of the insulation, and 1 l adapters
developed failures that were due to an improper or loose
connection between the adapter and the lead . Adapter
problems were managed by replacement with a new adapter
in eight, reconnection of the adapter to the lead in three and
replacement of the epicardial lead system with an endocar-
dial lead in five .
Analysis of lead and adapter failures by manufacturer and
model did not reveal significant differences in complication
rates. This was largely due to insufficient exposure of many
lead models (Tables 2 to 4) . Among the adapters, the
Telectronics model 033-415 bifurcated adapter was notewor-
thy for having a high failure rate of 20%, mostly related to
loose or improper connections between the adapter and the
sensing/pacing lead .
Clinical predictors of lead revisions . Specified clinical
variables were analyzed to test for an association with lead
revisions. With logistic regression methods for multivariate
statistics, no specified variables had a significant effect on
lead revisions . Using univariate analysis, only the lead type
and the use of an adapter were significant (p < 0 .05)
predictors of lead revisions. Epicardial leads were signifi-
cantly more likely than endocardial leads to require lead
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revisions . Patient age and gender, New York Heart Associ-
ation functional class, left ventricular ejection fraction,
indications for implantable cardioverter-defibrillator implan-
tation, surgical approach, concomitant drugs, presence of
other implanted devices (pacemakers) and lead model had no
statistically significant effect on the incidence of lead revi-
sions (p > 0 .05) (Table 1) .
Discussion
The major finding of this study is the high incidence of
sensing/pacing lead system complications associated with
the use of a newer generation implantable cardioverter-
defibrillator. Patients with lead failures most frequently
presented with multiple device detections or inappropriate
shocks secondary to oversensing or with elevated pacing
thresholds. The enhanced diagnostic capabilities of this
newer generation implantable cardioverter-defibrillator facil-
itated the noninvasive recognition of these lead problems .
Epicardial lead systems required significantly more revisions
than did endocardial systems. However, when adapter prob-
lems were excluded, the revision rates of endocardial and
epicardial leads were similar .
130
	
STAMBLER ET AL .
ICJ SENSING/PACING LEAD COMPLICATIONS
Comparisons with previous studies . Previous reports of
implantable cardioverter-defibrillator complications based
primarily on data collected by individual investigators have
suggested that the incidence of problems with the rate-
sensing leads is <2% (4-9) . The present study was a
prospective multicenter trial and thus may have reduced bias
with respect to implantation and follow-up. This may in part
explain the much higher complication rate of approximately
12% with sensing/pacing leads in this study . Most important,
however, the increased complication rate may be explained
by the limited diagnostic capabilities of the implantable
cardioverter-defibrillato:s used in earlier investigations, par-
ticularly the lack of recall of arrhythmic episodes. As many as
20% to 30% of patients with earlier implantable cardioverter-
defibrillators received unexplained implantable cardioverter-
defibrillator discharges (4,6,9,' . The appA'e priateness of these
discharges delivered to asymptomatic patients was difficult
to ascertain and has often been attributed to nonsustained
ventricular tachycardk or supraventricular tachycardia .
Noninvasive evaluation with earlier generation implantable
cardioverter-defibrillators in cases of suspected lead compli-
cations consisted of either X-ray evidence of a lead fracture,
a magnet test for sensing or transtelephonic monitoring
(10,11). It is possible that a substantial number of the
unexplained discharges from earlier devices were secondary
to undetected rate-sensing lead problems . More than 50% of
patients with documented lead problems in this study had
received inappropriate implantable cardioverter-defibrillator
shocks. In addition, because these earlier devices did not
have the capability to perform either bradycardia or anti-
tachycardia pacing, problems related specifically to high
pacing thresholds alone would have gone undetected if
sensing had been appropriate .
Enhanced diagnostic capabilities . This study suggests that
the enhanced diagnostic capabilities of this newer generation
implantable cardioverter-defibrillator improved the clinical
management of the patients with the device . These addi-
tional diagnostic functions include data logs of stored RR
intervals from detected events ; main timing event markers;
snapshots of stored intracardiac electrograms before, during
and after therapy delivery, and measurement of pacing
threshold and lead impedance . These features allowed the
clinician to noninvasively monitor the performance of the
implantable cardioverter-defibrillator and the integrity of the
pacing lead and to avoid unnecessary delays in appropriate
recognition of problems, such as sensing/pacing lead fail-
ures. In addition to tachyarrhythmia detection, the Guardian
ATP 4210 is also able to recognize noise and to disable
tachyarrhythmic therapy either through the noise detection
algorithm or by recognition of spontaneous reversion of the
noise episode
. Two thirds of the patients with lead compli-
cations had events that met the noise detection criteria . The
presence of noise detection events aided the clinician in the
diagnosis of a lead problem and avoided inappropriate
shocks or antitachycardia pacing for false arrhythmia detec-
tions .
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High lead revision rate . The majority of lead revisions
occurred in the 1st 6 months after device implantation .
However, there still was a broad time range to lead revision,
with a significant number of patients requiring revisions after
6 months. Actuarial analysis projected a relatively low lead
survival rate over time (89% at I year and 79% at 3 years)
compared with the rate when similar leads are used with
bradycardia devices. Overall survival of pacemaker leads in a
recent large registry at 5 years was 98 .5% (1) . Possible reasons
for the high lead revision rate when used with the implantable
cardioverter-defibrillator Include the frequent use of adapters,
the large size and weight of the pulse generator, location in the
abdominal pocket or damage from high energy implantable
cardioverter-defibrillator shocks . These data emphasize the
need for continued surveillance and testing of sensing/pacing
leads during follow-up of patients with an implantable cardio .
verter-defibrillator. Improved and more durable endocardfid
and epicardial lead systems and adapters are required . In
addition, advances in implantable cardioverter-defibrillator
technology may allow production of a much smaller pulse
generator and a pectoral implant .
DEud versus epicardial complications . Although a
study comparing the reliability of endocardial and epicardial
implantable cardioverter-defibrillator sensing/pacing leads
has not been previously reported, it has been suggested by
some investigators that endocardial leads have superior
reliability compared with epicardial leads when used with
the pacemaker-defibrillator (12-14) . In a multicenter study
using the Telectronics 4202/4203 implantable cardioverter-
defibrillator, Saksena et al . (14) found among 200 patients
that 17 patients with epicardial leads developed an increase
in pacing threshold, and 8 patients required lead revision for
pacing threshold problems with epicardial leads . Also in
support of the preference for endocardial leads for ventric-
ular pacing are several studies (3,15,16) of pacemaker com-
plications that have documented fewer pacing threshold
problems with endocardial than with epicardial leads . How-
ever, the present study was unable to reconfirm the superior
reliability of endocardial lead systems . When adapter prob-
lems were excluded, the complication rates of endocardial
and epicardial leads were similar . Lead dislodgement was
the most frequent source of problems with endocardial
leads, whereas disruption of insulation was the most com-
mon problem associated with epicardial leads . Problems
related to high pacing thresholds and lead fractures were
similar in epicardial and endocardial leads .
Adapter complications. Adapter complications accounted
for a substantial share of the implantable cardioverter-
defibrillator lead revisions, most notably with epicardial lead
systems. Although adapters have been used with pacemaker
leads for many years, limited published information is avail-
able on the reliability of these adapters . The adapters in this
study had a relatively low failure rate due to fracture or
insulation break, but a high incidence of problems related to
improper or loose connections that required adapter revi-
sion. One adapter (Telectronics model 033-415) was associ-
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ated with an unacceptably high incidence (2t%) of problems
particularly related to the use of its "push fit" VS1 connec-
tors. Elimination of lead adapters with the implantable
cardioverter-defibrillator can be accomplished by using
extended-length (i .e ., approximately 100-cm) bipolar endo-
cardial leads or the design of implantablc cardioverter-
defibrillator pulse generators that accept two epieardial leads
or a single endocardial lead directly into the header without
an adapter.
Clinical implications . Concerns have been raised with
regard to the economic impact of widespread implantable
cardioverter-defibrillator therapy and the current trend in the
exponential growth rates of implantable cardioverter-
defibrillator usage (17) . The data presented in this study,
if confirmed by other studies and with other implantable
cardioverter-defibrillators, raise important issues with re-
gard to the cost efficacy of the device and quality of life
of patients with implantable cardioverter-defibrillators .
Previous cost-benefit analyses of implantable cardioverter-
defibrillator device therapy have assumed a 3-year device
survival, with only limited costs included for implantable
cardioverter-defibrillator follow-up (1g) . The high failure rate
of the sensing/pacing leads in the present study will greatly
add to follow-up costs related to system monitoring, trou-
bleshooting, frequent clinic visits and lead replacement .
These additional costs could limit overall device efficacy,
current and future applications of this therapy, as well as
patient and physician acceptance of newer generation im-
plantable cardioverter-defibrillators .
Limitations of the study . A major limitation of this study
is the relatively short duration of the lead system and patient
follow-up. It is uncertain from the data whether lead com-
plications would continue to occur at the same rates in future
years or would decrease after a longer period after implan-
tation. Data from survival studies of implantable pacemaker
leads suggest that leads that survive beyond the 5th year
after implantation will have prolonged longevity, with few
additional failures occurring thereafter (1) . However, as our
data suggest, it is probably inappropriate to extrapolate the
reliability of implantable cardioverter-defibrillator leads on
the basis of their use in pacemakers . Another limitation of
the present study is that in the vast majority of cases, a
reliability analysis of the failed lead system was not avail-
able. The cause of the lead system failure was based on
reports and descriptions of the individual implanting clini-
cians. This is due to the low rate of return of explanted leads
and adapters to the manufacturer for physical analysis .
Because the choice of the sensing/pacing lead system was
made by the individual implanting clinicians, analysis of lead
failures by manufacturer and model was limited significantly
by inadequate exposure of many lead models . No effort was
made to recommend or specify which leads or adapters
should be used or in what number . This aspect of the study
therefore reflects the personal preferences of the various
contributors to the multicenter study. In addition, because
only one implantable cardioverter-defibrillator manufacturer
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and model was used in all patients, whether a similar
complication rate would be seen with other implantable
cardioverter-defibrillators remains to be definitively deter-
mined. A recent European multicenter study with another
third-generation implantable pacemaker cardioverter-
defibrillator, the Medtronic PC13, reported only three lead-
related complications among 102 implants (19) . That inves-
tigation, however, included a much smaller number of
implants and a shorter duration of follow-up and used only
epicardial screw-in electrodes (Medtronic model 6917A) .
The major limitations of this study can be addressed only
by a much larger and broader lead data base. The present
study indicates that such a data base should be a multicenter
national or worldwide registry, should include several dif-
ferent implantable cardioverter-defibrillators and sensing/
pacing leads by various manufacturers and should include at
least a 5-year follow-up . Such a registry has been contem-
plated for implanted pacemaker leads . The data on sensing/
pacing leads found in this report suggest that the pacemaker
lead registry should be broadened to include implantable
cardioverter-defibrillator leads as well .
Conclusions. This study demonstrated an unacceptably
high complication rate of the sensing/pacing leads used in a
newer generation implantable cardioverter-defibrillator.
Failures were seen with both epicardial and endocardial lead
systems and in many cases were due to adapter-related
problems . Careful patient follow-up and monitoring of these
leads using the enhanced diagnostic capabilities of newer
implantable cardioverter-defibrillators are warranted . Alter-
natives to currently available sensing/pacing lead systems
are required .
Addendum
Since submission of this report, additional patient fol-
low-up has continued to reconfirm the unacceptability high
complication rate with the sensing/pacing leads . As of
March 1, 1993, a total of 527 implantations with the Guardian
ATP 4210 were performed . During an average of 14 .5
months of follow-up, there were 86 sensing/pacing lead
system complications (16 .3%), of which 51 were related to
leads and 35 to adapters
. Seventeen of the 51 lead-related
complications were lead dislodgements, and 11 were lead
insulation breaks. Twenty-two of the 35 adapter-related
complications were adapter connection problems . Of the 27
patients in this study whose device was identified as mani-
festing noise detection from an unknown source, 5 patients
subsequently required sensing/pacing lead system revision,
and l had a suspected adapter connection problem but could
not undergo lead revision because of end-stage congestive
heart failure .
We gratefully acknowledge the excellent assistance of Kay Lentz in the
preparation of the manuscript and the contribution of John DerCola in
supplying material for a ligure .
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Appendix
Guardian ATP 4210 Multicenter Primary
Investigators and Institutions
Ualted Sues: William Batsford,
MD, Yale-New
Haven Hospital, New
Haven, CT,, Robert Bauernfeind. MD, St. Francis Medical Center, Peoria,
IL; Karen Beckman, MD,
University of Oklahoma Health Sciences/Hillcrest
Medical Center, Oklahoma City, OK; Sheldon Brownstein, MD . St . Vincent
Medical Center, Toledo, OH . Lon Castle, MD, Cleveland Clinic Foundation .
Cleveland, OH: Thomas Deering, MD, Piedmont Hospital, Atlanta, GA ;
Kenneth Ellenbogen, MD, Medical College of Virginia/McGuire VA Medical
Center, Richmond. VA: N. A . Mark Estes, MD, New England Medical
Center, Boston, MA; Jay Franklin, MD. Baylor Medical Center, Dallas, TX ;
Ted Freihling, MD, Fairfax Hospital, Fairfax, VA ; Ken Haisty, MD, North
Carolina Baptist Hospital, Winston Salem, NC ; Richard Kehoe, MD. Illinois
Masonic Medical Center, Chicago, IL : Charles Love. MD. Ohio State
Urtvc-city, Columbus, OH: Richard Luceri, MD, Holy Cross Hospital, Ft .
Loudr-date, FL : Gerald Naccarelli, MD, University of Texas Health Sci-
ences, Houston, TX; Antonio Pacifico, MD, Methodist Hospital, Houston,
TX; ictor Parsonnet, MD, Newark Beth Israel Medical Center, Newark, NJ ;
Tom Petropoulos, MD, Christ Hospital, Oak Lawn, IL ; Sanjeev Saksena,
MD,
General Hospital at Passaic, Passaic, NJ ; Aqun Sharma, MD, Sutter
Memorial HospitallMercy General Hospital, Sacramento, CA ; Igor Singer,
MD, Humana HospitallUniversity of Louisville, Louisville, KY ; Ferdinand
Venditti, MD, Lahey Clinic Hospital, Burlington, MA ; Paul Walter, MD,
Emory University, Atlanta, GA ; Douglas Zipes, MD, Indiana Universityl
Purdue UniversitylSt. Francis Hospital, Indianapolis, IN .
A : Michael John Davis, MD. Royal Perth Hospital, Perth, West-
ern Australia ; Kevin Hellestrand, MD, Royal North Shore Hospital. Sydney.
New South Wales ; Dennis Kuchar, MD . St . Vincents Hospital, Sydney . New
South Wales ; Anne Powell, MD. The Alfred Hospital. Melbourne, Victoria;
Wayne Stafford, MD, Prince Charles Hospital, Brisbane, Queensland . John
Uther. MD, Westmead Hospital, Sydney, New South Wales ; Jitu Vohra. MD.
Royal Melbourne Hospital, Melbourne, Victoria .
Paul Dorian, MD . Toronto General Hospital/St. Michaels Has.
pitallToronto Western Hospital . Toronto, Ontario; Sajadhussein Gulam-
husein . MD, University ofAlberta, Edmonton, Alberta; Charles R . Kerr, MD,
Vancouver University Hospital, Vancouver, British Columbia; Michael
Rosengarten. MD. Montreal General Hospital, Montreal. Quebec; Denis
Ray, MD, Montreal Institute of Cardiology, Montreal, Quebec;
Anthony
S. L. Tang, MD, Ottawa Civic Heart Institute, Ottawa. Ontario : William
Williams, MD . Hospital for Sick Children, Toronto. Ontario; Raymond Yea,
MD, University Hospital, London, Ontario .
Mogens Moller, MD. Odense Hospital, Odense, Paul-Eric
Bloch Thomsen, MD, Skejby Sygehus, Skejby.
France : Etienne Allot, MD, Nancy Hospital, Nancy; Jean Francois
Leckrq, MD, LariboisiPre Hospital. Pans ; Hervd Lemarec, MD, Nantes
Hospital, Nantes ; Patrice Scanu, MD . CHU Caen, Caen;
Paul Touboul, MD,
Hospital Cardio-Lyon . Lyon .
Germany: Johannes Brachman, MD, Heidelberg University Hospital.
Heidelberg. Semi San, MD. Hamburg University Hospital, Hamburg: Nor-
bert Trese, MD. University ofMainz, Mainz.
Karel Den Dulk, MD, Academic Hospital, Maastricht .
S ea: Carina Blomstrom-Lundgvist, MD, University Hospital, Lund.
United : A
. John Camm, MD, St. Georges Hospital, London ;
Campbell Cowan, MD, Leeds General Infirmary, Leeds .
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